File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Intensive consolidation chemotherapy for newly diagnosed acute myeloid leukemia using a regime containing moderate dose cytosine arabinoside and mitoxantrone

TitleIntensive consolidation chemotherapy for newly diagnosed acute myeloid leukemia using a regime containing moderate dose cytosine arabinoside and mitoxantrone
Authors
KeywordsAcute myeloid leukemia
Mitoxantrone
Issue Date1995
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.anti-cancerdrugs.com
Citation
Anti-Cancer Drugs, 1995, v. 6 n. 2, p. 224-228 How to Cite?
AbstractFifty patients with previously untreated acute myeloid leukemia were treated with an induction regimen consisting of cytosine arabinoside 100 mg/m 2 per day by 18 h i.v. infusion for 7 days, daunorubicin 50 mg/m 2 per day by i.v. bolus injection for 3 days and etoposide 75 mg/m 2 per day by 1 h i.v. infusion for 7 days. Thirty seven of them (74%) went into complete remission (CR) and they all then received two consecutive courses of consolidation chemotherapy consisting of cytosine arabinoside 500 mg/m 2 per day by 1 h i.v, infusion every 12 h for 4 days (total eight doses) and mitoxantrone 12 mg/m 2 daily by 30 min i.v. infusion for 3 days. They were followed by maintenance chemotherapy with cytosine arabinoside and thioguanine 2 monthly. With a median follow up time of 24 months, 20 of the 37 complete responders had relapsed (54%). The disease-free survival (DFS) of 37 on patients and the overall survival of all patients at 24 months were 37 and 44%, respectively. Age of patients and number of courses of induction chemotherapy to achieve CR were significant factors predicting DFS. Myelosuppression was the major toxic side effect. Ten patients had prolonged marrow suppression following consolidation chemotherapy. In conclusion, despite the significant myelosuppression observed, overall improvement in treatment outcome was not demonstrable with the use of this intensive consolidation therapy.
Persistent Identifierhttp://hdl.handle.net/10722/88545
ISSN
2015 Impact Factor: 2.268
2015 SCImago Journal Rankings: 0.795
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiang, Ren_HK
dc.contributor.authorChan, TKen_HK
dc.contributor.authorChu, YCen_HK
dc.contributor.authorChan, Jen_HK
dc.contributor.authorChiu, Een_HK
dc.contributor.authorLie, Aen_HK
dc.contributor.authorKwong, YLen_HK
dc.contributor.authorYeung, YMen_HK
dc.contributor.authorChan, LCen_HK
dc.contributor.authorWong, KFen_HK
dc.contributor.authorAu, KLen_HK
dc.date.accessioned2010-09-06T09:44:46Z-
dc.date.available2010-09-06T09:44:46Z-
dc.date.issued1995en_HK
dc.identifier.citationAnti-Cancer Drugs, 1995, v. 6 n. 2, p. 224-228en_HK
dc.identifier.issn0959-4973en_HK
dc.identifier.urihttp://hdl.handle.net/10722/88545-
dc.description.abstractFifty patients with previously untreated acute myeloid leukemia were treated with an induction regimen consisting of cytosine arabinoside 100 mg/m 2 per day by 18 h i.v. infusion for 7 days, daunorubicin 50 mg/m 2 per day by i.v. bolus injection for 3 days and etoposide 75 mg/m 2 per day by 1 h i.v. infusion for 7 days. Thirty seven of them (74%) went into complete remission (CR) and they all then received two consecutive courses of consolidation chemotherapy consisting of cytosine arabinoside 500 mg/m 2 per day by 1 h i.v, infusion every 12 h for 4 days (total eight doses) and mitoxantrone 12 mg/m 2 daily by 30 min i.v. infusion for 3 days. They were followed by maintenance chemotherapy with cytosine arabinoside and thioguanine 2 monthly. With a median follow up time of 24 months, 20 of the 37 complete responders had relapsed (54%). The disease-free survival (DFS) of 37 on patients and the overall survival of all patients at 24 months were 37 and 44%, respectively. Age of patients and number of courses of induction chemotherapy to achieve CR were significant factors predicting DFS. Myelosuppression was the major toxic side effect. Ten patients had prolonged marrow suppression following consolidation chemotherapy. In conclusion, despite the significant myelosuppression observed, overall improvement in treatment outcome was not demonstrable with the use of this intensive consolidation therapy.en_HK
dc.languageengen_HK
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.anti-cancerdrugs.comen_HK
dc.relation.ispartofAnti-Cancer Drugsen_HK
dc.rightsAnticancer Drugs. Copyright © Lippincott Williams & Wilkins, Ltd.en_HK
dc.subjectAcute myeloid leukemiaen_HK
dc.subjectMitoxantroneen_HK
dc.subject.meshAdolescent-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - therapeutic use-
dc.subject.meshCytarabine - administration and dosage - adverse effects-
dc.subject.meshLeukemia, Myeloid, Acute - drug therapy - mortality-
dc.subject.meshMitoxantrone - administration and dosage - adverse effects-
dc.titleIntensive consolidation chemotherapy for newly diagnosed acute myeloid leukemia using a regime containing moderate dose cytosine arabinoside and mitoxantroneen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0959-4973&volume=6&issue=2&spage=224&epage=228&date=1995&atitle=Intensive+consolidation+chemotherapy+for+newly+diagnosed+acute+myeloid+leukaemia+using+a+regime+containing+moderate+dose+cytosine+arabinoside+and+mitoxantroneen_HK
dc.identifier.emailLiang, R:rliang@hku.hken_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.emailChan, LC:chanlc@hkucc.hku.hken_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.identifier.authorityChan, LC=rp00373en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid7795271-
dc.identifier.scopuseid_2-s2.0-0028900863en_HK
dc.identifier.hkuros5112en_HK
dc.identifier.volume6en_HK
dc.identifier.issue2en_HK
dc.identifier.spage224en_HK
dc.identifier.epage228en_HK
dc.identifier.isiWOS:A1995QU08700005-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK
dc.identifier.scopusauthoridChan, TK=7402687762en_HK
dc.identifier.scopusauthoridChu, YC=55209144200en_HK
dc.identifier.scopusauthoridChan, J=7403287057en_HK
dc.identifier.scopusauthoridChiu, E=24827833600en_HK
dc.identifier.scopusauthoridLie, A=24284842400en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.scopusauthoridYeung, YM=9941021000en_HK
dc.identifier.scopusauthoridChan, LC=7403540707en_HK
dc.identifier.scopusauthoridWong, KF=7404759860en_HK
dc.identifier.scopusauthoridAu, KL=36854880800en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats